Prophylaxis of migraine headache

CMAJ. Canadian Medical Association Journal

Volumn 182, Issue 7, 2010, Pages

  Pringsheim, Tamara ^a   Davenport, W Jeptha ^a   Becker, Werner J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BOTULINUM TOXIN A; CANDESARTAN; FLUNARIZINE; GABAPENTIN; LISINOPRIL; MAGNESIUM; NADOLOL; PETASITES HYBRIDUS EXTRACT; PIZOTIFEN; PROPRANOLOL; RIBOFLAVIN; TANACETUM PARTHENIUM EXTRACT; TOPIRAMATE; UBIDECARENONE; VALPROATE SEMISODIUM; VENLAFAXINE; VERAPAMIL;

ADULT; ANOREXIA; ANTICONVULSANT THERAPY; ANTIHYPERTENSIVE THERAPY; ASTHENIA; BEDTIME DOSAGE; BLOOD PRESSURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; FATIGUE; HEART RATE; HERBAL MEDICINE; HUMAN; MEMORY DISORDER; META ANALYSIS; MIGRAINE; NAUSEA; PARESTHESIA; PROFESSIONAL KNOWLEDGE; PSYCHOPHARMACOTHERAPY; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TANACETUM PARTHENIUM; TASTE DISORDER; TREMOR; VITAMIN SUPPLEMENTATION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 77953320248     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.081657     Document Type: Review

References (81)

1. International Headache Society. The international classification of headache disorders. 2nd ed. Cephalalgia 2004;24(Suppl 1):1-160.
2. Silberstein SD and the United States Headache Consortium. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review). Neurology 2000;55:754-762
3. Members of the European Federation of Neurological Societies task force: Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol 2006;13:560-572
4. Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology 2006;66:1894-1898
5. Jelinski SE, Becker WJ, Christie SN, et al. Clinical features and pharmacological treatment of migraine patients referred to headache specialists in Canada. Cephalalgia 2006;26:578-588
6. Pryse-Phillips WEM, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice. CMAJ 1997;156:1273-1287 (Pubitemid 27223150)
7. Lipton RB, Bigal ME, Diamond M, et al.; the AMPP advisory group. Migraine prevalence, disease burden, and the need for preventative therapy. Neurology 2007; 68:343-349
8. Ziegler DK, Hurwitz A, Preskorn S, et al. Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. Arch Neurol 1993; 50:825-830 (Pubitemid 23229308)
9. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281-286
10. Klapper, J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997;2:103-108
11. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention. JAMA 2004;291:965-973
12. Diener H-C, Bussone G, Van Oene JC, et al. TOPMAT-MIG 201 (TOP-Chrome) study group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007;27:814-823
13. Mei D, Ferraro D, Zelano G, et al. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol 2006;29:269-275
14. Lipton RB. Tracing transformation. Chronic migraine classification, progression and epidemiology. Neurology 2009;72(Suppl 5):S3-7.
15. Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004;62:788-790 (Pubitemid 38298959)
16. Limmroth V, Biondi D, Pfeil J, et al. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache 2007;47:13-21.
17. Ad hoc committee on classification of headache: classification of headache. JAMA 1962;179:717-718
18. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended release tablets in migraine prophylaxis. Neurology 2002;58:1652-1659
19. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992;12:81-84
20. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple blind, placebo controlled crossover study. Neurology 1994;44:647-651 (Pubitemid 24129990)
21. Shaygannejad V, Janghorbani M, Ghorbani A, et al. Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache 2006;46:642-648
22. Diener H, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis. J Neurol 2004;251:943-950
23. Mei D, Capuano A, Vollono C, et al. Topiramate in migraine prophylaxis: a randomized double blind versus placebo study. Neurol Sci 2004;25:245-250
24. Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention. Arch Neurol 2004;61:490-495
25. Storey JR, Calder CS, Hart DE, et al. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001;41:968-975
26. Gupta P, Singh S, Goyal V, et al. Low dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache 2007;47:402-412
27. Silberstein SD, Hulihan J, Karim MR, et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther 2006;28:1002-1011
28. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001;41:119-128
29. Di Trapani B, Mei D, Marra C, et al. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo controlled study. Clin Ter 2000;151:145-148 (Pubitemid 30482218)
30. Bank J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 1994;34:476-478
31. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979;36:695-699
32. Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis. J Neurol Neurosurg Psychiatry 1973;36:684-690
33. Ziegler DK, Hurwitz A, Hassanein RS. Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol 1987;44:486-489 (Pubitemid 17061928)
34. Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005;45:144-152
35. Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004;107:44-48
36. Linde K, Rossnagel K. Propranolol for migraine prophylaxis [review]. Cochrane Database Syst Rev 2004;(2):CD003225.
37. Ryan RE Sr., Ryan RE Jr., Sudilovsky A. Nadolol and placebo comparison study in the prophylactic treatment of migraine. Panminerva Med 1982;24:89-94.
38. Freitag FG, Diamond S. Nadolol and placebo comparison study in the prophylactic treatment of migraine. J Am Osteopath Assoc 1984;84:343-347 (Pubitemid 15191329)
39. Al Deeb SM, Biary N, Bahou Y, et al. Flunarizine in migraine: a double-blind placebo-controlled study (in a Saudi population). Headache 1992;32:461-462
40. Frenken CW, Nuijten ST. Flunarizine, a new preventive approach to migraine. Clin Neurol Neurosurg 1984;86:17-20.
41. Louis P. A double-blind placebo-controlled prophylactic study of flunarizine in migraine. Headache 1981;21:235-239 (Pubitemid 12227344)
42. Mendenopoulos G, Manafi TH, Logothetis I, et al. Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cephalalgia 1985;5:31-37 (Pubitemid 15104392)
43. Sorensen PS, Hansen K, Olesen J. A placebo-controlled, double-blind cross-over trial of flunarizine in common migraine. Cephalalgia 1986;6:7-14. (Pubitemid 16080293)
44. Thomas M, Behari M, Ahuja GK. Flunarizine in migraine prophylaxis: an Indian trial. Headache 1991;31:613-615
45. Cerbo R, Casacchia M, Formisano R, et al. Flunarizine-pizotifen single dose double blind crossover trial in migraine prophylaxis. Cephalalgia 1986;6:15-18
46. Louis P, Spierlings EL. Comparison of flunarizine and pizotifen in migraine treatment: a double-blind study. Cephalalgia 1982;2:197-203.
47. Rascol A, Montastruc JL, Rascol O. Flunarizine versus pizotifen: a double blind study in the prophylaxis of migraine. Headache 1986;26:83-85 (Pubitemid 16124195)
48. Markley HG, Cheronis J, Piepho RW. Verapamil in prophylactic therapy of migraine. Neurology 1984;34:973-976
49. Soloman GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine: a double-blind, placebo-controlled trial. JAMA 1983;250:2500-2502
50. Schrader H, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomized, placebo-controlled, crossover study. BMJ 2001;322:1-5.
51. Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker. JAMA 2003;289:65-69
52. Bellevance AJ, Meloche JP. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache 1990;30:710-715
53. Carroll JD, Maclay WP. Pizotifen (BC-105) in migraine prophylaxis. Curr Med Res Opin 1975;3:68-71.
54. Lawrence ER, Hossain M, Littlestone W. Sanomigran for migraine prophylaxis; controlled multicentre trial in general practice. Headache 1977;17:109-112
55. Osterman PO. A comparison between placebo, pizotifen and divascan in migraine prophylaxis. Acta Neurol Scand 1977;56:17-28.
56. Sjaastad O, Stensrud P. Appraisal of BC-105 in migraine prophylaxis. Acta Neurol Scand 1969;45:594-600.
57. Aurora SK, Gawel M, Brandes JL, et al. Botulinum toxin type A prophylactic treatment of episodic migraine: a randomized double blind placebo controlled exploratory study. Headache 2007;47:486-499
58. Elkind AH, O'Carroll P, Blumenfeld A, et al. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006;7:688-696
59. Evers S, Vollmer-Haase J, Schwaag S, et al. Botulinum toxin A in the prophylactic treatment of migraine - a randomized, double-blind, placebo-controlled study. Cephalalgia 2004;24:838-843
60. Relja M, Poole AC, Schoenen J, et al. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A for the prophylaxis of episodic migraine headaches. Cephalalgia 2007;27: 492-503.
61. Saper JR, Mathew NT, Loder EW, et al. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type A injection sites and doses in the prevention of episodic migraine. Pain Med 2007;8:478-485
62. Vo AH, Satori R, Jabbari B, et al. Botulinum toxin type-A in the prevention of migraine: a double-blind controlled trial. Aviat Space Environ Med 2007;78:B113-8.
63. Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type A as a migraine preventative treatment. Headache 2000;40:445-450
64. Anand KS, Prasad A, Singh MM, et al. Botulinum toxin type A in prophylactic treatment of migraine. Am J Ther 2006;13:183-187
65. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology 1998;50:466-470 (Pubitemid 28119790)
66. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew in migraine prophylaxis: a randomized trial. Headache 2004;44:885-890
67. Pfaffenrath V, Wessely P, Meyer C, et al. G'bel H, Fischer M. Magnesium in the prophylaxis of migraine - a double-blind, placebo-controlled study. Cephalalgia 1996;16:436-440
68. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multicentre, placebo-controlled and double blind randomized study. Cephalalgia 1996;16:257-263
69. DeWeerdt CJ, Bootsma HPR, Hendriks H. Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine 1996;3:225-230 (Pubitemid 126504561)
70. Diener HC, Pfaffenrath V, Schnitker J, et al. Efficacy and safety of 6.25 mg TID feverfew CO2 extract (MIG-99) in migraine prevention - a randomized, doubleblind, multicentre, placebo controlled study. Cephalalgia 2005;25:1031-1041
71. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988;8604:189-192
72. Pfaffenrath V, Diener H, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis - a double blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002;22:523-532
73. Sándor P, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized, controlled trial. Neurology 2005;64:713-715 (Pubitemid 40261904)
74. Lipton RB, Gobel K, Einhaupl KM, et al. Petasites hybridus root (butterbur) is an effective preventative treatment for migraine. Neurology 2004;63:2240-2244
75. Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol 2004;51:89-97.
76. Harris RP, Helfand MH, Woolf SH, et al. Current methods of the United States Preventive Services Task Force: a review of the process. Am J Prev Med 2001;20(Suppl 3): 21-35.
77. Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:961-965 (Pubitemid 40388443)
78. Fraunfelder FW, Fraunfelder FT, Keates EU. Topiramate-associated acute, bilateral, secondary angle closure glaucoma. Ophthalmology 2004;111:109-111
79. Health Canada. Magnesium. Ottawa (ON): The Department; 2007. Available: www.hc-sc.gc.ca/dhp-mps/prodnatur/applications/licenprod/monograph/ mono-magnesium-eng.php#fn3 (accessed 2009 Sept. 2)
80. Wöeber C, Wöeber-Bingol C, Koch G, et al. Long-term results of migraine prophylaxis with flunarizine and beta-blockers. Cephalalgia 1991;11:251-256
81. Diener HC, Agosti R, Allais G, et al.; for the TOPMAT-MIG 303 investigator group. Cessation versus continuation of 6-month migraine preventative therapy with topiramate (PROMPT): a randomised, double-blind placebo-controlled trial. Lancet Neurol 2007;6:1054-1062